GLP-1 Drugs and Skin Aging: What Dermatologists Are Seeing in 2026

GLP-1 Drugs and Skin Aging: What Dermatologists Are Seeing in 2026

GLP-1 receptor agonists — a class of medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) that mimic the gut hormone glucagon-like peptide-1 to suppress appetite and regulate blood sugar — have become one of the most-prescribed drug classes in modern medicine. KFF Health Tracking Poll data from November 2025 found that 12% of US adults are currently taking a GLP-1 drug, approximately 31 million Americans by population extrapolation, up from just 6% in May 2024. But as their use skyrockets, so does a pressing dermatological question: what are these drugs doing to our skin?

At major dermatology gatherings in 2026 — from the Music City SCALE meeting to the GLP-1 Effects on Skin Inflammation, Skin Aging and the Cardiometabolic Syndrome Summit in New York — leading clinicians are assembling a clearer, and often sobering, picture of the aesthetic trade-offs patients need to understand before, during, and after GLP-1 therapy.

What exactly is "GLP-1 skin," and why are dermatologists alarmed?

For many people taking GLP-1 medications like Ozempic, Wegovy, Mounjaro, or Zepbound, an unexpected side effect shows up in the mirror: thinner, drier, more hollow-looking skin. Dermatologists are increasingly referring to this as "GLP-1 skin" — a combination of volume loss, skin laxity, dehydration, and accelerated collagen decline that can happen after significant medication-driven weight loss.

At the 2026 GLP-1 Effects on Skin Inflammation, Skin Aging and the Cardiometabolic Syndrome Summit, Doris Day, MD, FAAD, professor of dermatology at NYU Grossman School of Medicine, stated: "We know that weight reduction, while it can reduce systemic inflammation, can also cause negative effects as well." She emphasized the "aesthetic cost" that clinicians see regularly, noting that GLP-1s may induce hair loss and cause facial volume loss and skin sagging — effects now referred to clinically as "GLP-1 face" or "Ozempic face."

Terrence Keaney, MD, presenting at the 2026 Music City SCALE meeting, noted that aesthetic outcomes are often more complex than patients anticipate — despite the demonstrated metabolic and health benefits. "The aesthetic consequences of GLP-1 agonists are not all sunshine and rainbows," he cautioned.

What does rapid weight loss actually do to facial structure and collagen?

Facial volume loss — the hallmark of "Ozempic face" — reflects fat and bony compartment changes plus histologic shifts after major weight loss, including fewer thick collagen fibers and increased elastic fiber density that causes laxity. In plain terms, the scaffolding that holds your face in place literally thins and loses its tension.

The most vulnerable zones are the temples, cheeks, tear troughs, jawline, marionette lines, and nasolabial folds — the most common areas of volume loss or wrinkles after semaglutide treatment. Research confirms that the most pronounced losses occur in the medial cheek, sub-orbicularis oculi (under-eye), and temporal fat pads — producing hollow temples, flattened cheeks, deepened nasolabial folds, sunken under-eyes, and a more visible jawline edge.

Evidence suggests that GLP-1 and dual GLP-1/GIP receptor agonists may contribute to rapid facial volume loss, dermal fat atrophy, and periocular hollowing through a multifactorial mechanism, involving both weight-loss-related fat depletion and potential modulation of adipocyte differentiation.

A 2026 Allergan Aesthetics healthcare provider survey reported 61% of GLP-1 patients experiencing midface volume loss, 50% experiencing skin laxity, and 35% experiencing facial wrinkles or folds as their primary concerns.

Is there a direct cellular aging effect beyond weight loss alone?

GLP-1 (glucagon-like peptide-1) is an incretin hormone involved in glucose regulation. GLP-1 receptor agonists are widely used in the treatment of type 2 diabetes and obesity, as well as cardiovascular risk reduction — but recent evidence suggests that GLP-1 receptors are expressed in cutaneous tissues, and their role in skin homeostasis and aging remains insufficiently clarified.

A peer-reviewed 2026 study published in the Journal of Clinical Medicine reviewed experimental and clinical data specifically on this question. Experimental data indicate that GLP-1 receptor agonists may promote wound healing through modulation of inflammatory pathways, enhancement of keratinocyte migration, improved microvascular perfusion, and support of fibroblast function — suggesting a complex, dual nature: the drugs may carry some skin-protective biology, even as the weight-loss mechanism simultaneously depletes volume and collagen density.

A systematic review covering 51 studies found that 34 reported adverse dermatologic effects — including hypersensitivity, injection-site reactions, pruritus, urticaria, and immune-mediated conditions — while 17 studies described beneficial outcomes, such as improvements in psoriasis, reduced hidradenitis suppurativa flares, enhanced wound healing, anti-aging potential, and decreased inflammation. The skin story, in other words, is genuinely two-sided.

What about hair loss — how serious is it and what causes it?

GLP-1–associated hair loss appears multifactorial: telogen effluvium (a shock-shedding response triggered by rapid physiological change) combined with inadequate caloric intake and micronutrient deficiencies — particularly vitamin D, zinc, selenium, iron, and ferritin — are common contributors, warranting early laboratory screening and protein/calorie counseling.

GLP-1s slow gastric emptying and motility, and some patients experience diarrhea — especially when initiating therapy. Those patients could be at higher risk for cutaneous adverse events such as dull, saggy skin or hair loss, because nutritional losses often exceed what they are taking in. This underscores why dermatologists are now advocating for integrated nutritional support as a front-line intervention alongside any aesthetic plan.

When should patients see a dermatologist — and what is the treatment framework?

Keaney encouraged dermatologists to engage with patients before or early during their GLP-1 journey, rather than waiting until substantial weight loss has already occurred. He divided intervention strategies into three phases: drug initiation, active weight-loss progression, and post–goal weight refinement.

At drug initiation, the focus is on prevention — including skin care optimization, early collagen-stimulating energy-based procedures, and hair-loss prevention strategies. This proactive window is arguably the most important one for preserving skin quality and structural integrity.

For at-home collagen support between professional visits, energy-based devices that stimulate fibroblast activity — the cells responsible for producing collagen and elastin — are gaining attention. The SKINDELÚX Fibroblast Plasma Pen uses plasma energy to micro-stimulate the skin surface, encouraging fibroblast regeneration in areas prone to laxity. While it is not a replacement for clinical intervention, it can be a practical complementary tool for users who want to actively support their skin texture and firmness during a GLP-1 regimen. Always consult your dermatologist before integrating any energy device into your routine.

Dr. Jane Yoo, MD, a board-certified dermatologist, approaches GLP-1 patients by first identifying which structural changes are present — volume loss, skin laxity, texture changes, jowling, or under-eye hollowing — because each problem requires a different treatment strategy. The key word in 2026, she notes, is restraint: the era of overfilling has passed, and today's aesthetic philosophy emphasizes subtle, natural-looking restoration rather than overcorrection.

Keaney has also emphasized that the GLP-1 story is still evolving, and that dermatologists are likely to see a growing influx of patients who may not have previously engaged with aesthetic medicine — making education and early intervention more critical than ever.

Are there any skin benefits from GLP-1 therapy that patients should know about?

Despite the aesthetic challenges, the science is not uniformly negative. Recent data from the TOGETHER-PsO trial demonstrated that 27.1% of participants receiving ixekizumab and tirzepatide together reached complete skin clearance (PASI 100) and at least 10% weight loss, compared with just 5.8% of patients treated with ixekizumab alone. This landmark finding suggests GLP-1 class drugs may enhance the efficacy of biologic treatments for inflammatory skin diseases like psoriasis.

Emerging evidence suggests these agents also exert direct dermatologic effects — including potential reductions in chronic skin inflammation — which may benefit patients with conditions like hidradenitis suppurativa, psoriasis, and rosacea. The clinical picture is one of risk-benefit balance that deserves an individualized, proactive approach.

What is the bottom line for anyone currently on or considering GLP-1 therapy?

"Ozempic face" represents a genuine clinical concern — significant facial volume loss, sagging, and dullness resulting from both rapid weight loss and underlying cellular changes in the skin — and dermatologists are now unpacking the science and using the opportunity to play a more integral role in the multidisciplinary care of GLP-1 patients. The consensus emerging from 2026 summits is clear: GLP-1 therapy warrants a dermatology conversation, ideally before the first dose.

If you are already on a GLP-1 medication and noticing changes in your skin's firmness, texture, or fullness, book a consultation with a board-certified dermatologist to discuss your timeline and options. And to support your skin's collagen-building capacity at home between professional treatments, explore energy-based tools like the SKINDELÚX Fibroblast Plasma Pen — a non-invasive option designed to keep fibroblast activity working in your favour. Remember: no device replaces medical advice, but your daily routine can meaningfully support what your dermatologist starts.

Frequently Asked Questions

What is "Ozempic face" and who gets it?
"Ozempic face" is a colloquial term for a cluster of facial changes — including hollowed cheeks, sunken temples, deepened nasolabial folds, jowling, and overall skin laxity — that can occur following rapid, significant weight loss on GLP-1 receptor agonist medications. It can affect anyone who loses weight quickly on these drugs, though the degree varies based on age, baseline skin quality, genetics, and the rate of weight loss.
Do GLP-1 drugs directly damage skin, or is it just the weight loss?
Both mechanisms are under investigation. Most dermatologists agree the primary driver is rapid fat depletion in facial compartments, which outpaces the skin's ability to retract. However, research from 2025–2026 suggests GLP-1 receptors are expressed in cutaneous tissue and may also directly influence fibroblast function, keratinocyte migration, and adipocyte behavior — meaning there could be a cellular component beyond weight loss alone. More long-term data are needed.
How common is GLP-1-associated hair loss, and is it permanent?
Hair loss linked to GLP-1 therapy is increasingly documented and appears to stem from a combination of telogen effluvium (a temporary shock-shedding phase), caloric restriction, and micronutrient deficiencies including vitamin D, zinc, iron, and selenium. In most cases it is not permanent, but early laboratory screening and nutritional counseling are important. Speak with your dermatologist if you notice significant shedding within the first few months of therapy.
When is the best time to start skin-protective treatments while on GLP-1 drugs?
The clinical consensus from dermatology meetings in 2026 — including the SCALE meeting and the GLP-1 Effects on Skin Aging Summit — is that the best time to start is at drug initiation or even before. Early collagen-stimulating procedures, optimized skincare, nutritional support, and hair-loss prevention strategies are most effective when started proactively, rather than after significant volume and structural changes have already occurred.
Can GLP-1 drugs actually help certain skin conditions?
Yes. Emerging data suggest GLP-1 receptor agonists can benefit inflammatory skin conditions including psoriasis, hidradenitis suppurativa, and potentially rosacea, partly by reducing systemic inflammation and metabolic load on the skin. The TOGETHER-PsO trial in 2026 showed that adding tirzepatide to biologic therapy significantly improved complete skin clearance rates in psoriasis patients with obesity. The dermatological profile of these drugs is genuinely dual-sided.
What at-home options support skin firmness during GLP-1 therapy?
Clinicians recommend a multi-pronged approach: a collagen-supportive diet rich in protein and micronutrients, evidence-based topicals (retinoids, peptides, vitamin C), consistent SPF use, and energy-based home devices designed to stimulate fibroblast activity. These tools complement but do not replace professional treatments like bio-stimulators, radiofrequency, or hyaluronic acid-based procedures. Always discuss any new regimen with your dermatologist.

Sources:

Back to Plasma Pen

You may also like

View all